GuidelineEuropean journal of nuclear medicine and molecular imaging2024
Joint EANM-SNMMI guideline on the role of 2-[
Guideline in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective.European journal of nuclear medicine and molecular imaging · 2024Pooled it
- 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7).Breast (Edinburgh, Scotland) · 2024Guideline
- A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Prognostic value of [European journal of nuclear medicine and molecular imaging · 2026Article
- The anatomical distribution of metabolic tumor burden provides prognostic information beyond whole-body ¹⁸F-FDG PET/CT metrics in de novo metastatic HER2-positive breast cancer.Annals of nuclear medicine · 2026Article
- Diagnostic performance ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Evaluation of the time‑of‑flight-enhanced deep learning image reconstruction method inPhysical and engineering sciences in medicine · 2026Article
- Automatic metabolic breast cancer staging using [¹⁸F]FDG PET/CT: comparison with nuclear medicine physician-based and clinical staging.European journal of nuclear medicine and molecular imaging · 2026Article
- [European journal of nuclear medicine and molecular imaging · 2026Article
- Prognostic relevance of [18F]FDG PET/CT in triple-negative breast cancer: Results from the triple negative (TRINE)-PET trial.European journal of nuclear medicine and molecular imaging · 2026Article
- Stage-dependent performance and molecular subtype-specific relapse patterns on same-session [18F]FDG PET/contrast-enhanced CT in breast cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- Diagnostic value of [Scientific reports · 2026Observational
- AlEuropean journal of nuclear medicine and molecular imaging · 2026Article
- How to optimise breast cancer staging with contrast-enhanced mammography: current evidence and clinical implications.Insights into imaging · 2026Review
- The proportion, clinical predictors, and prognostic impact of hypometabolic estrogen receptor-positive primary breast cancer on baseline [ 18 F] fluorodeoxyglucose PET.Nuclear medicine communications · 2026Article
- From imaging heterogeneity to clinical decision: a novel imaging biomarker based on bone marrow kinetics for advanced NSCLC patients in partial response.EJNMMI research · 2026Article
- Positron-emission tomography as a predictor of response to first-line cyclin-dependent kinase 4/6 inhibitors in patients with metastatic ER-positive HER2-negative breast cancer.NPJ breast cancer · 2026Article
- From One Cancer to Two: [¹⁸F]FES PET/CT Redirected Diagnosis and Therapy in a Metastatic Breast Cancer Patient.Clinical nuclear medicine · 2026Article
- Is re-irradiation combined with chemotherapy an option for inoperable local recurrence of previously irradiated breast cancer? A collection of cases.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Fluorine-18-Labeled Nucleotide Analogs Targeting Ecto-5'-Nucleotidase (CD73) for Positron Emission Tomography Imaging of Solid Tumors.Angewandte Chemie (International ed. in English) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThere is much literature about the role of 2-[ PURPOSE: To provide an organized, international, state-of-the-art, and multidisciplinary guideline, led by experts of two nuclear medicine societies (EANM and SNMMI) and representation of important societies in the field of BC (ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA).
methodsLiterature review and expert discussion were performed with the aim of collecting updated information regarding the role of 2-[
resultsQuantitative PET features (SUV, MTV, TLG) are valuable prognostic parameters. In baseline staging, 2-[
conclusion2-[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.